

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxml624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 18	CA/CAPplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	4	DEC 18	CA/CAPplus patent kind codes updated
NEWS	5	DEC 18	MARPAT to CA/CAPplus accession number crossover limit increased to 50,000
NEWS	6	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	7	DEC 27	CA/CAPplus enhanced with more pre-1907 records
NEWS	8	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	9	JAN 16	CA/CAPplus Company Name Thesaurus enhanced and reloaded
NEWS	10	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	11	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	12	JAN 22	CA/CAPplus updated with revised CAS roles
NEWS	13	JAN 22	CA/CAPplus enhanced with patent applications from India
NEWS	14	JAN 29	PHAR reloaded with new search and display fields
NEWS	15	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	17	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	18	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	19	FEB 26	MEDLINE reloaded with enhancements
NEWS	20	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS	21	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	22	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	23	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS	24	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	25	MAR 16	CASREACT coverage extended
NEWS	26	MAR 20	MARPAT now updated daily
NEWS	27	MAR 22	LWPI reloaded
NEWS	28	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	29	MAR 30	INPADOCDB will replace INPADOC on STN
NEWS	30	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS EXPRESS	NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		
NEWS X25	X.25 communication option no longer available		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:59:48 ON 05 APR 2007

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 16:00:00 ON 05 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 APR 2007 HIGHEST RN 929190-51-2

DICTIONARY FILE UPDATES: 4 APR 2007 HIGHEST RN 929190-51-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10822975g.str



```

chain nodes :
10 11 14
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
2-14 8-10 9-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 2-14 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 9-11

```

G1: Cy, Cb, Hy

G2: C, H, O

G3: O, N, C

G4: C, N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



G1 Cy, Cb, Hy

G2 C, H, O

G3 O, N, C

G4 C, N

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sam

SAMPLE SEARCH INITIATED 16:00:25 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1488 TO ITERATE

100.0% PROCESSED 1488 ITERATIONS

12 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 27446 TO 32074  
PROJECTED ANSWERS: 33 TO 447

L2 12 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 16:00:37 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 28601 TO ITERATE

100.0% PROCESSED 28601 ITERATIONS  
SEARCH TIME: 00.00.01

217 ANSWERS

L3 217 SEA SSS FUL L1

=> fil cap

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

FULL ESTIMATED COST

172.10 172.31

FILE 'CAPLUS' ENTERED AT 16:00:41 ON 05 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Apr 2007 VOL 146 ISS 15

FILE LAST UPDATED: 4 Apr 2007 (20070404/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 5 L3

=> s l4 not (2007/so or 2006/so or 2005/so)

181296 2007/SO

819510 2006/SO

872711 2005/SO

L5 4 L4 NOT (2007/SO OR 2006/SO OR 2005/SO)

=> s l5 ibib hitstr abs 1-4

MISSING OPERATOR L5 IBIB

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> d l5 ibib hitstr abs 1-4

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:905619 CAPLUS

DOCUMENT NUMBER: 141:379939

TITLE: Preparation of pyrazolo[4,3-d]pyrimidin-7-one and pyrazolo[3,4-c]pyridin-7-one compounds as cannabinoid receptor ligands

INVENTOR(S): Carpino, Philip A.; Griffith, David A.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 38 pp.  
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004214838	A1	20041028	US 2004-822988	20040412
US 7141669	B2	20061128		
CA 2523205	A1	20041104	CA 2004-2523205	20040413
WO 2004094417	A1	20041104	WO 2004-IB1262	20040413
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1622902	A1	20060208	EP 2004-727068	20040413
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009689	A	20060418	BR 2004-9689	20040413
JP 2006524222	T	20061026	JP 2006-506527	20040413
NL 1026029	A1	20041027	NL 2004-1026029	20040423
NL 1026029	C2	20050705		

PRIORITY APPLN. INFO.: US 2003-464916P P 20030423  
WO 2004-IB1262 W 20040413

OTHER SOURCE(S): MARPAT 141:379939


IT 784193-08-4P 784193-09-5P 784193-10-8P  
784193-11-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolo[4,3-d]pyrimidin-7-one and pyrazolo[3,4-c]pyridin-7-one compds. as cannabinoid receptor ligands)


RN 784193-08-4 CAPLUS

CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-2,4-dihydro- (9CI) (CA INDEX NAME)




RN 784193-09-5 CAPLUS

CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 2-(2-chlorophenyl)-2,4-dihydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 784193-10-8 CAPLUS

CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-5-ethyl-2,4-dihydro- (9CI) (CA INDEX NAME)




RN 784193-11-9 CAPLUS


CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-2,4-dihydro-5-methyl- (9CI) (CA INDEX NAME)



GI



I



II

AB The title compds. I [A = N, CR2 (wherein R2 = H, alkyl, haloalkyl,

alkoxy); R0, R1 = (un)substituted (hetero)aryl; R3 = H, (un)substituted alkyl, alkoxy; R4 = alkyl, aryl, heteroaryl, etc.] that act as cannabinoid receptor ligands and therefore are useful in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, were prepared E.g., a 2-step synthesis of II, starting from 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxylic acid, was given. All the exemplified compds. were tested in the CB-1 receptor binding assay and provided a range of binding activities from 0.09 to 453 nM. The pharmaceutical composition comprising the compound I is claimed.

REFERENCE COUNT: 131 THERE ARE 131 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:905618 CAPLUS

DOCUMENT NUMBER: 141:379938

TITLE: Preparation of pyrazolo[4,3-d]pyrimidine and pyrazolo[3,4-c]pyridine compounds as cannabinoid receptor ligands

INVENTOR(S): Griffith, David A.; Hammond, Marlys

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 76 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004214837	A1	20041028	US 2004-822975	20040412
CA 2520842	A1	20041111	CA 2004-2520842	20040420
WO 2004096801	A1	20041111	WO 2004-IB1418	20040420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1622904	A1	20060208	EP 2004-728385	20040420
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009634	A	20060425	BR 2004-9634	20040420
JP 2006524226	T	20061026	JP 2006-506585	20040420
JP 3893141	B2	20070314		
NL 1026030	A1	20041101	NL 2004-1026030	20040423
NL 1026030	C2	20050705		

PRIORITY APPLN. INFO.: US 2003-464918P P 20030423  
US 2004-540048P P 20040129  
WO 2004-IB1418 W 20040420

OTHER SOURCE(S): MARPAT 141:379938


IT 784207-12-1P 784208-08-8P 784208-41-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrazolo[4,3-d]pyrimidine and pyrazolo[3,4-c]pyridine compds. for treating disorders modulated by a cannabinoid receptor antagonist)


RN 784207-12-1 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid, 5-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 784208-08-8 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,5-diazabicyclo[2.2.1]hept-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 784208-41-9 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-bromophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropoxy)-5-methyl- (9CI) (CA INDEX NAME)





IT	784206-66-2P	784206-67-3P	784206-68-4P
	784206-69-5P	784206-70-8P	784206-71-9P
	784206-72-0P	784206-73-1P	784206-74-2P
	784206-75-3P	784206-76-4P	784206-77-5P
	784206-78-6P	784206-79-7P	784206-80-0P
	784206-81-1P	784206-82-2P	784206-83-3P
	784206-84-4P	784206-85-5P	784206-86-6P
	784206-87-7P	784206-88-8P	784206-89-9P
	784206-90-2P	784206-91-3P	784206-92-4P
	784206-93-5P	784206-94-6P	784206-95-7P
	784206-96-8P	784206-97-9P	784206-98-0P
	784206-99-1P	784207-00-7P	784207-01-8P
	784207-02-9P	784207-03-0P	784207-04-1P
	784207-05-2P	784207-06-3P	784207-07-4P
	784207-08-5P	784207-09-6P	784207-10-9P
	784207-11-0P	784207-13-2P	784207-14-3P
	784207-15-4P	784207-16-5P	784207-17-6P
	784207-18-7P	784207-19-8P	784207-20-1P
	784207-21-2P	784207-22-3P	784207-23-4P
	784207-24-5P	784207-25-6P	784207-26-7P
	784207-27-8P	784207-28-9P	784207-29-0P
	784207-30-3P	784207-31-4P	784207-32-5P
	784207-33-6P	784207-34-7P	784207-35-8P
	784207-36-9P	784207-37-0P	784207-38-1P
	784207-39-2P	784207-40-5P	784207-41-6P
	784207-42-7P	784207-43-8P	784207-44-9P
	784207-45-0P	784207-46-1P	784207-47-2P
	784207-48-3P	784207-49-4P	784207-50-7P
	784207-51-8P	784207-52-9P	784207-53-0P
	784207-54-1P	784207-55-2P	784207-56-3P
	784207-57-4P	784207-58-5P	784207-59-6P
	784207-60-9P	784207-61-0P	784207-62-1P
	784207-63-2P	784207-64-3P	784207-65-4P
	784207-66-5P	784207-67-6P	784207-68-7P
	784207-69-8P	784207-70-1P	784207-71-2P
	784207-72-3P	784207-73-4P	784207-74-5P
	784207-75-6P	784207-76-7P	784207-77-8P
	784207-78-9P	784207-79-0P	784207-80-3P
	784207-81-4P	784207-82-5P	784207-83-6P
	784207-84-7P	784207-85-8P	784207-86-9P
	784207-87-0P	784207-88-1P	784207-89-2P
	784207-90-5P	784207-91-6P	784207-92-7P
	784207-93-8P	784207-94-9P	784207-95-0P
	784207-96-1P	784207-97-2P	784207-98-3P
	784207-99-4P	784208-00-0P	784208-01-1P
	784208-02-2P	784208-03-3P	784208-04-4P
	784208-05-5P	784208-06-6P	784208-07-7P
	784208-09-9P	784208-10-2P	784208-11-3P
	784208-12-4P	784208-13-5P	784208-14-6P


784208-15-7P 784208-16-8P 784208-17-9P  
 784208-18-0P 784208-19-1P 784208-20-4P  
 784208-21-5P 784208-22-6P 784208-23-7P  
 784208-24-8P 784208-25-9P 784208-26-0P  
 784208-27-1P 784208-28-2P 784208-30-6P  
 784208-31-7P 784208-32-8P 784208-33-9P  
 784208-34-0P 784208-35-1P 784208-36-2P  
 784208-37-3P 784208-38-4P 784208-39-5P  
 784208-40-8P 784208-42-0P 784208-43-1P  
 784208-44-2P 784208-45-3P 784208-46-4P  
 784208-47-5P 784208-50-0P 784208-51-1P  
 784208-52-2P 784208-53-3P 784208-58-8P  
 784208-59-9P 784208-60-2P 784208-61-3P  
 784208-62-4P 784208-63-5P 784208-64-6P  
 784208-65-7P 784208-66-8P 784208-67-9P  
 784208-68-0P 784208-69-1P 784208-70-4P  
 784208-71-5P 784208-72-6P 784208-73-7P  
 784208-74-8P 784208-75-9P 784208-76-0P  
 784208-77-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of pyrazolo[4,3-d]pyrimidine and pyrazolo[3,4-c]pyridine  
 compds. for treating disorders modulated by a cannabinoid receptor  
 antagonist)



RN 784206-66-2 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(1-  
 pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 784206-67-3 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-(4-chlorophenyl)-2-(2,4-  
 dichlorophenyl)-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 784206-68-4 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 784206-69-5 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidine, 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 784206-70-8 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidine, 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-7-

(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 784206-71-9 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-bicyclo[2.2.1]hept-2-yl-3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 784206-72-0 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-7-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 784206-73-1 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 784206-74-2 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 784206-75-3 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 784206-76-4 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N,N-diethyl- (9CI) (CA INDEX NAME)





RN 784206-77-5 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-bicyclo[2.2.1]hept-2-yl-2-(2-chlorophenyl)-3-(4-chlorophenyl)- (9CI) (CA INDEX NAME)





RN 784206-78-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-one, 8-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 784206-79-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 784206-80-0 CAPLUS

CN Morpholine, 4-[[1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-phenyl-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 784206-81-1 CAPLUS


CN Carbamic acid, [1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-pyrrolidinyl]methyl-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)



RN 784206-82-2 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[2-(1-piperidinylmethyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)






RN 784206-83-3 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-, ethyl ester (9CI). (CA INDEX NAME)




RN 784206-84-4 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 3-[3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-7,8-difluoro-2,3,4,5-tetrahydro- (9CI)  
(CA INDEX NAME)




RN 784206-85-5 CAPLUS

CN Carbamic acid, [1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 784206-86-6 CAPLUS

CN 2-Piperidinemethanamine, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 784206-87-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)





RN 784206-88-8 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-7-[2-[2-(1-pyrrolidinyl)ethyl]-1-piperidinyl]-1-ethoxy carbonyl (9CI) (CA INDEX NAME)




RN 784206-89-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 784206-90-2 CAPLUS

CN Acetamide, N-[1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 784206-91-3 CAPLUS

CN 4-Piperidinol, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 784206-92-4 CAPLUS

CN Spiro[naphthalene-1(2H),4'-piperidine], 1'-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3,4-dihydro-5-methoxy-(9CI) (CA INDEX NAME)



RN 784206-93-5 CAPLUS


CN 3-Piperidinemethanol, 1-[3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-(9CI) (CA INDEX NAME)



RN 784206-94-6 CAPLUS


CN 3-Pyrrolidinamine, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N,N-dimethyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 784206-95-7 CAPLUS

CN 1,4-Dioxo-8-azaspiro[4.5]decane, 8-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 784206-96-8 CAPLUS

CN Spiro[naphthalene-1(2H),4'-piperidine], 1'-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3,4-dihydro-6-methoxy-(9CI) (CA INDEX NAME)




RN 784206-97-9 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-7-[4-(phenylmethyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 784206-98-0 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)- (9CI) (CA INDEX NAME)




RN 784206-99-1 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[(3aR,6aS)-tetrahydro-2,2-dimethyl-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 784207-00-7 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[(3R,5S)-3,5-dimethyl-1-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 784207-01-8 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[3-(3-methylphenyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 784207-02-9 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(4,4-dimethyl-1-piperidiny)- (9CI) (CA INDEX NAME)




RN 784207-03-0 CAPLUS

CN 4,7-Epoxy-1H-isoindole, 2-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]octahydro-4-methyl- (9CI) (CA INDEX NAME)



RN 784207-04-1 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[2-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1-piperidiny]- (9CI) (CA INDEX NAME)



RN 784207-05-2 CAPLUS

CN Quinoline, 1-[3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-2H-pyrazolo[4,3-


d]pyrimidin-7-yl]decahydro- (9CI) (CA INDEX NAME)



RN 784207-06-3. CAPLUS


CN 3,4-Pyrrolidinediol, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 784207-07-4 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,5-dimethyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 784207-08-5 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,3-dimethyl-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 784207-09-6 CAPLUS

CN Spiro[1H-indene-1,4'-piperidine], 1'-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 784207-10-9 CAPLUS


CN 2-Piperidinemethanamine, 1-[3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 784207-11-0 CAPLUS


CN 3-Pyrrolidinol, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 784207-13-2 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 7-[1,4'-bipiperidin]-1'-yl-2-(2-chlorophenyl)-3-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 784207-14-3 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(3-cyclohexyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 784207-15-4 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784207-16-5 CAPLUS


CN 3-Pyrrolidinol, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-(1-methylethoxy)-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 784207-17-6 CAPLUS

CN Spiro[1H-2-benzopyran-1,3'-piperidine], 1'-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3,4-dihydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 784207-18-7 CAPLUS

CN 4-Piperidinecarbonitrile, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 784207-19-8 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 784207-20-1 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[3-[(2,3-dihydro-5-methoxy-1H-inden-4-yl)oxy]-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)






RN 784207-21-2 CAPLUS

CN 3-Piperidineacetic acid, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784207-22-3 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 784207-23-4 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)




RN 784207-24-5 CAPLUS

CN 4-Piperidineacetonitrile, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-α-phenyl- (9CI) (CA INDEX NAME)




RN 784207-25-6 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[3-(2-pyridinyloxy)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 784207-26-7 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(3-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 784207-27-8 CAPLUS


CN Spiro[1H-indene-1,4'-piperidine], 1'-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 784207-28-9 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[(1S,5R)-1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 784207-29-0 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid, 5-[3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 784207-30-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-[3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 784207-31-4 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 7-(3-bromo-8-azabicyclo[3.2.1]oct-8-yl)-2-(2-chlorophenyl)-3-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 784207-32-5 CAPLUS

CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 784207-33-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-(ethylamino)- (9CI) (CA INDEX NAME)




RN 784207-34-7 CAPLUS

CN 1-Thia-4,8-diazaspiro[4.5]decane, 8-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 784207-35-8 CAPLUS

CN 2,5,7-Triazaspiro[3.4]octan-8-one, 2-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-5-methyl- (9CI) (CA INDEX NAME)




RN 784207-36-9 CAPLUS

CN Cyclohexanol, 4-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-, trans- (9CI) (CA INDEX NAME)



Relative stereochemistry.






RN 784207-37-0 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 7-(3-bromo-8-azabicyclo[3.2.1]oct-8-yl)-3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 784207-38-1 CAPLUS

CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 784207-39-2 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-3-carbonitrile, 8-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 784207-40-5 CAPLUS

CN 4-Piperidinol, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 784207-41-6 CAPLUS

CN 4-Piperidinol, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 784207-42-7 CAPLUS

CN 4-Piperidinol, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 784207-43-8 CAPLUS

CN [1,3'-Bipyrrolidine]-3'-carboxamide, 1'-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 784207-44-9 CAPLUS

CN 3-Pyrrolidinecarboxamide, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 784207-45-0 CAPLUS

CN 3-Pyrrolidinecarboxamide, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 784207-46-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-3-carboxamide, 8-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-(1-pyrrolidinyl)- (9CI)  
(CA INDEX NAME)




RN 784207-47-2 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-ethyl- (9CI) (CA INDEX NAME)





RN 784207-48-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 784207-49-4 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 784207-50-7 CAPLUS

CN 4-Piperidinol, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 784207-51-8 CAPLUS

CN 3-Pyrrolidinol, 1-[3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-ethyl- (9CI) (CA INDEX NAME)



RN 784207-52-9 CAPLUS


CN 3-Pyrrolidinol, 1-[3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 784207-53-0 CAPLUS


CN 3-Pyrrolidinol, 1-[3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)






RN 784207-54-1 CAPLUS

CN 3-Pyrrolidinol, 1-[3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 784207-55-2 CAPLUS

CN 3-Azetidinecarboxamide, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-(methylamino)- (9CI) (CA INDEX NAME)




RN 784207-56-3 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(4-methylcyclohexyl)- (9CI) (CA INDEX NAME)




RN 784207-57-4 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-tricyclo[3.3.1.1<sup>3,7</sup>]dec-2-yl- (9CI) (CA INDEX NAME)



RN 784207-58-5 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(3-methylcyclohexyl)- (9CI) (CA INDEX NAME)



RN 784207-59-6 CAPLUS

CN Cyclopentanecarboxylic acid, 2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-, ethyl ester, (1R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 784207-60-9 CAPLUS

CN Cyclopentanol, 2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-, (1R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 784207-61-0 CAPLUS


CN Cyclohexanol, 2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 784207-62-1 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-cycloheptyl- (9CI) (CA INDEX NAME)




RN 784207-63-2 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-cyclobutyl- (9CI) (CA INDEX NAME)




RN 784207-64-3 CAPLUS

CN 1,3-Propanediol, 2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 784207-65-4 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(1-methyl-1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 784207-66-5 CAPLUS

CN Cyclopentanemethanol, 1-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 784207-67-6 CAPLUS

CN 1-Propanol, 2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 784207-68-7 CAPLUS

CN 1,4-Pentanediamine, N4-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N1,N1-diethyl- (9CI) (CA INDEX NAME)




RN 784207-69-8 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 784207-70-1 CAPLUS

CN Benzenepropanol, β-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 784207-71-2 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)



RN 784207-72-3 CAPLUS




CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine,. 2-(2-chlorophenyl)-3-(4-chlorophenyl)-  
N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 784207-73-4 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-  
N-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 784207-74-5 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-  
2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-(phenylmethyl)-,  
(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 784207-75-6 CAPLUS

CN Pyrrolidine, 1-[(2S)-2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784207-76-7 CAPLUS

CN Phenol, 4-[(2S)-2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784207-77-8 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[(1R)-1-cyclohexylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784207-78-9 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-  
N-[(1R)-1-(4-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784207-79-0 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-  
N-[(1S)-1-(4-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 784207-80-3 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-  
N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)



RN 784207-81-4 CAPLUS


CN 1H-Inden-2-ol, 1-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2,3-dihydro-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 784207-82-5 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[1-methyl-2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 784207-83-6 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 784207-84-7 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 784207-85-8 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 784207-86-9 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[6-(1-piperidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 784207-87-0 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-[6-(1-azetidiny)-3-pyridinyl]-2-(2-chlorophenyl)-3-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 784207-88-1 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 784207-89-2 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[(6-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 784207-90-5 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)






RN 784207-91-6 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 784207-92-7 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-(1H-benzimidazol-2-ylmethyl)-2-(2-chlorophenyl)-3-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 784207-93-8 CAPLUS

CN 2-Propanol, 1-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 784207-94-9 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 784207-95-0 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)



RN 784207-96-1 CAPLUS


CN 4-Piperidinecarbonitrile, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 784207-97-2 CAPLUS


CN 3-Piperidinol, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 784207-98-3 CAPLUS

CN 3-Pyrrolidinamine, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 784207-99-4 CAPLUS


CN 1-Propanone, 1-[1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-phenyl-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 784208-00-0 CAPLUS


CN Cyclohexanol, 2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 784208-01-1 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-cyclohexyl- (9CI) (CA INDEX NAME)




RN 784208-02-2 CAPLUS

CN 3-Azetidinecarboxamide, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)




RN 784208-03-3 CAPLUS

CN 3-Azetidinecarboxamide, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 784208-04-4 CAPLUS


CN 2,5,7-Triazaspiro[3.4]octan-8-one, 2-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 784208-05-5 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 784208-06-6 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 784208-07-7 CAPLUS


CN 4-Piperidinamine, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 784208-09-9 CAPLUS


CN 3-Pyrrolidinamine, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)






RN 784208-10-2 CAPLUS

CN 3-Pyrrolidinamine, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 784208-11-3 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 784208-12-4 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(5-cyclopentyl-2,5-diazabicyclo[2.2.1]hept-2-yl)- (9CI) (CA INDEX NAME)





RN 784208-13-5 CAPLUS

CN 3-Pyrrolidinamine, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 784208-14-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 784208-15-7 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[5-(1-methylethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)



RN 784208-16-8 CAPLUS


CN 3-Pyrrolidinamine, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 784208-17-9 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[3-(1-pyrrolidinyl)-8-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 784208-18-0 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 784208-19-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 784208-20-4 CAPLUS

CN 3-Pyrrolidinamine, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N-cyclopentyl-N-methyl- (9CI) (CA INDEX NAME)




RN 784208-21-5 CAPLUS

CN 3-Pyrrolidinamine, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 784208-22-6 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[5-(methylsulfonyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)




RN 784208-23-7 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-5-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 784208-24-8 CAPLUS


CN 2,5-Diazabicyclo[2.2.1]heptane-2-sulfonamide, 5-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 784208-25-9 CAPLUS


CN 1-Piperazinesulfonamide, 4-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)






RN 784208-26-0 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-5-[(2,2,2-trifluoroethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 784208-27-1 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[4-(methylsulfonyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 784208-28-2 CAPLUS

CN Piperazine, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 784208-30-6 CAPLUS

CN Piperazine, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-(ethylsulfonyl)- (9CI) (CA INDEX NAME)




RN 784208-31-7 CAPLUS

CN Piperazine, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-[(2,2,2-trifluoroethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 784208-32-8 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[[1-(phenylmethyl)-3-pyrrolidinyl]oxy]- (9CI) (CA INDEX NAME)




RN 784208-33-9 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 784208-34-0 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[[1-(diphenylmethyl)-3-azetidinyl]oxy]- (9CI) (CA INDEX NAME)




RN 784208-35-1 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-5-ethyl-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 784208-36-2 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-5-(1-methylethyl)-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 784208-37-3 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-methoxyphenyl)-5-methyl-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 784208-38-4 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-ethoxy-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 784208-39-5 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 784208-40-8 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluorobutoxy)-5-methyl- (9CI) (CA INDEX NAME)




RN 784208-42-0 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-bromophenyl)-3-(4-methoxyphenyl)-5-methyl-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 784208-43-1 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-bromophenyl)-7-(2,2-difluoropropoxy)-3-(4-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 784208-44-2 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 3-(4-bromophenyl)-2-(2-chlorophenyl)-7-(2,2-difluoropropoxy)-5-methyl- (9CI) (CA INDEX NAME)




RN 784208-45-3 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-7-(2,2-difluoropropoxy)-3-(4-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 784208-46-4 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-7-(1-methylethoxy)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 784208-47-5 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chloro-4-methylphenyl)-5-methyl-7-(2,2,2-trifluoroethoxy)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 784208-50-0 CAPLUS


CN Benzonitrile, 2-[3-(4-chlorophenyl)-5-methyl-7-(2,2,2-trifluoroethoxy)-2H-pyrazolo[4,3-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)






RN 784208-51-1 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-ethoxy- (9CI) (CA INDEX NAME)




RN 784208-52-2 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-propoxy- (9CI) (CA INDEX NAME)




RN 784208-53-3 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 7-butoxy-2-(2-chlorophenyl)-3-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 784208-58-8 CAPLUS

CN 4-Piperidinecarboxamide, 1-[3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-(ethylamino)- (9CI) (CA INDEX NAME)




RN 784208-59-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 784208-60-2 CAPLUS

CN 3-Piperidinol, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)





RN 784208-61-3 CAPLUS

CN 4-Piperidinecarbonitrile, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)





RN 784208-62-4 CAPLUS

CN 4-Piperidinecarbonitrile, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 784208-63-5 CAPLUS

CN 4-Piperidinecarbonitrile, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 784208-64-6 CAPLUS

CN 3-Pyrrolidinamine, 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 784208-65-7 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 784208-66-8 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-methoxy- (9CI) (CA INDEX NAME)




RN 784208-67-9 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)- (9CI) (CA INDEX NAME)




RN 784208-68-0 CAPLUS

CN Cyclopentanecarboxylic acid, 2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784208-69-1 CAPLUS

CN Cyclopentanol, 2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 784208-70-4 CAPLUS

CN Cyclohexanol, 2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 784208-71-5 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(2,6-dimethylcyclohexyl)- (9CI) (CA INDEX NAME)



RN 784208-72-6 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(1,1-dimethylpropyl)- (9CI) (CA INDEX NAME)



RN 784208-73-7 CAPLUS

CN Pyrrolidine, 1-[2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-


d]pyrimidin-7-yl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 784208-74-8 CAPLUS

CN Phenol, 4-[2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 784208-75-9 CAPLUS



CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(1-cyclohexylethyl)- (9CI) (CA INDEX NAME)






RN 784208-76-0 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[1-(4-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 784208-77-1 CAPLUS

CN 1H-Inden-2-ol, 1-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2,3-dihydro- (9CI) (CA INDEX NAME)




IT 784193-08-4P 784193-10-8P 784208-56-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolo[4,3-d]pyrimidine and pyrazolo[3,4-c]pyridine compds. for treating disorders modulated by a cannabinoid receptor antagonist)


RN 784193-08-4 CAPLUS

CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-2,4-dihydro- (9CI) (CA INDEX NAME)




RN 784193-10-8 CAPLUS

CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-5-ethyl-2,4-dihydro- (9CI) (CA INDEX NAME)




RN 784208-56-6 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 7-chloro-2-(2-chlorophenyl)-3-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



GI



AB The title compds. I [A = N, CR2 (wherein R2 = H, alkyl, haloalkyl, alkoxy); R0, R1 = (un)substituted (hetero)aryl; R3 = H, alkyl, haloalkyl, alkoxy; R4 = (un)substituted pyrrolidino, piperidino, piperazino, etc.] that act as cannabinoid receptor ligands and therefore are useful in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, were prepared Thus, reacting 7-chloro-3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-2H-pyrazolo[3,4-c]pyridine with 4-ethylaminopiperidine-4-carboxylic acid amide (prepns. given) afforded 78% II. All the exemplified compds. (over 190) were tested in the CB-1 receptor binding assay and showed a range of binding activities from 0.2 nM to 1.6  $\mu$ M. The pharmaceutical composition comprising the compound I is claimed.

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:147157 CAPLUS

DOCUMENT NUMBER: 140:321638

TITLE: Imino-C-nucleoside Synthesis: Heteroaryl Lithium Carbanion Additions to a Carbohydrate Cyclic Imine and Nitron

AUTHOR(S): Evans, Gary B.; Furneaux, Richard H.; Hausler, Herwig; Larsen, Janus S.; Tyler, Peter C.

CORPORATE SOURCE: Carbohydrate Chemistry, Industrial Research Limited, Lower Hutt, N. Z.

SOURCE: Journal of Organic Chemistry (2004), 69(6), 2217-2220  
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:321638

IT 607389-23-1P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of imino-C-nucleosides via heteroaryl lithium carbanion addns. to a carbohydrate cyclic imine and nitron)

RN 607389-23-1 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 3-[(3aS,4S,6R,6aR)-6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]tetrahydro-2,2-dimethyl-4H-1,3-dioxolo[4,5-c]pyrrol-4-yl]-7-methoxy-2-(tetrahydro-2H-pyran-2-yl)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



AB Promotion by Lewis acid of the addition of some aryllithiums to a carbohydrate-based imine, which has allowed a more facile synthesis of some imino-C-nucleoside analogs, is described. Use of the corresponding nitron does not assist in some cases, but lithiated acetonitrile adds to it efficiently to give a product from which further C-nucleoside analogs can be derived.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:777802 CAPLUS

DOCUMENT NUMBER: 139:277119

TITLE: Preparation of C-nucleosides as inhibitors of nucleoside phosphorylases and nucleosidases

INVENTOR(S): Furneaux, Richard Hubert; Schramm, Vern L.; Tyler, Peter Charles; Evans, Gary Brian

PATENT ASSIGNEE(S): Industrial Research Limited, N. Z.; Albert Einstein College of Medicine of Yeshiva University

SOURCE: PCT Int. Appl., 63 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080620	A1	20031002	WO 2003-NZ50	20030325
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004110772	A1	20040610	US 2003-395636	20030324
US 7098334	B2	20060829		

CA 2480470	A1	20031002	CA 2003-2480470	20030325
AU 2003215969	A1	20031008	AU 2003-215969	20030325
EP 1490373	A1	20041229	EP 2003-745042	20030325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005527544	T	20050915	JP 2003-578374	20030325
PRIORITY APPLN. INFO.:			NZ 2002-517970	A 20020325
			WO 2003-NZ50	W 20030325

OTHER SOURCE(S): MARPAT 139:277119

IT 607389-23-1P 607389-24-2P 607389-25-3P

607389-26-4P


RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of C-nucleosides as inhibitors of nucleoside phosphorylases and nucleosidases)

RN 607389-23-1 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 3-[(3aS,4S,6R,6aR)-6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl]tetrahydro-2,2-dimethyl-4H-1,3-dioxolo[4,5-c]pyrrol-4-yl]-7-methoxy-2-(tetrahydro-2H-pyran-2-yl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 607389-24-2 CAPLUS

CN 5H-1,3-Dioxolo[4,5-c]pyrrole-5-carboxylic acid, 4-[7-amino-2-(tetrahydro-2H-pyran-2-yl)-2H-pyrazolo[4,3-d]pyrimidin-3-yl]-6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl]tetrahydro-2,2-dimethyl-, 1,1-dimethylethyl ester, (3aS,4S,6R,6aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607389-25-3 CAPLUS

CN 5H-1,3-Dioxolo[4,5-c]pyrrole-5-carboxylic acid, 4-[7-(benzoylamino)-2-(tetrahydro-2H-pyran-2-yl)-2H-pyrazolo[4,3-d]pyrimidin-3-yl]tetrahydro-6-(hydroxymethyl)-2,2-dimethyl-, 1,1-dimethylethyl ester, (3aS,4S,6R,6aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 607389-26-4 CAPLUS

CN 5H-1,3-Dioxolo[4,5-c]pyrrole-5-carboxylic acid, 4-[(acetylthio)methyl]-6-[7-(benzoylamino)-2-(tetrahydro-2H-pyran-2-yl)-2H-pyrazolo[4,3-d]pyrimidin-3-yl]tetrahydro-2,2-dimethyl-, 1,1-dimethylethyl ester, (3aR,4S,6S,6aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



I

AB The present invention relates to compds. of the general formula I, where R is selected from halogen, optionally substituted alkyl, aralkyl and aryl, OH, NH<sub>2</sub>, NHR<sub>1</sub>, NR<sub>1</sub>R<sub>2</sub> and SR<sub>3</sub>, where R<sub>1</sub>-R<sub>3</sub> are each optionally substituted alkyl, aralkyl or aryl groups; B is selected from NH<sub>2</sub> and NHR<sub>4</sub>, where R<sub>4</sub> is an optionally substituted alkyl, aralkyl or aryl group; X is selected from H, OH and halogen; and Z is selected from H, Q, SQ and OQ, where Q is an optionally substituted alkyl, aralkyl or aryl group; or a tautomer thereof; or a pharmaceutically acceptable salt thereof; or an ester thereof; or a prodrug thereof; with the proviso that the stereochem. of the aza-sugar moiety is D-ribo- or 2'-deoxy-D-erythro-, which are inhibitors of 5'-methylthioadenosine phosphorylases and 5'-methylthioadenosine nucleosidases (MTAP and MTAN), the invention also relates to the use of these compds. in treatment of diseases and infections including cancer, bacterial infections and parasitic infections, and to pharmaceutical compns. containing the compds. Thus, I (X = OH, Z = SPh, A = CH, B = NH<sub>2</sub>) was prepared and tested in vitro as MTAP and MTAN inhibitor (K<sub>i</sub> = 46 ± 3 pM and 890.0 ± 120 pM resp.).

REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

28.52

200.83

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.12

-3.12

STN INTERNATIONAL LOGOFF AT 16:02:31 ON 05 APR 2007